Agenus (AGEN) Partner GSK (GSK) Submits for EU Approval of Shingles Vaccine

November 25, 2016 11:46 AM EST

Get the Pulse of the Market with StreetInsider.com's Pulse Picks. Get your Free Trial here.

Agenus (NASDAQ: AGEN) stock is flat today despite some positive news from partner GlaxoSmithKline (NYSE: GSK). GSK announced today the regulatory submission of a Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA) seeking approval for its candidate shingles vaccine, ShingrixTM, for the prevention of herpes zoster (shingles) in people aged 50 years or over.

The GSK proprietary AS01 adjuvant system contains QS-21 Stimulon® adjuvant licensed from Antigenics LLC, a wholly owned subsidiary of Agenus Inc. (NASDAQ: AGEN), MPL and liposomes.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

FDA, Trader Talk

Add Your Comment